MA-ALAKA’I-TECHNOLOGIES
29.5.2019 23:02:12 CEST | Business Wire | Press release
Today, Alaka’i Technologies unveiled Skai, the world’s first hydrogen fuel cell powered air mobility solution designed to transform the way the world moves. From its sleek, uncluttered design, radically simple and safe electric vertical takeoff and landing (eVTOL) vehicle, to its fuel source - a system that runs entirely on hydrogen fuel cells - Skai is poised to be one of the safest, cleanest and most versatile air mobility solutions introduced to the world.
Skai’s core team members are nationally-recognized aerospace experts, engineers, and veteran pilots who have served in top-level positions at NASA, Raytheon, Beech, Cirrus, DayJet, and the Department of Defense who collaborated on the vision of solving some of the world’s most-pressing global challenges across transportation, energy and the environment. Skai is co-designed by Designworks, the design innovation studio for the BMW Group, to leverage its creative expertise to help shape a world-class vehicle. The result is Skai, stripped away of all unnecessary complexity, waste and possible points of failure, leaving the most essential elements for the craft and optimizing them for the most intuitive experience.
“This remarkably impressive team have come together to build on our collective experience to finally realize our singular, critical vision to launch Skai and transform transportation,” said Brian Morrison, Co-Founder, President and Chief Technology Officer of Alaka’i Technologies. “Skai offers practical, real-life solutions to everything from relieving traffic congestion to delivering supplies during natural disasters. Skai is set to offer affordable, realistic applications in the commercial, private, freight, and personal air mobility markets.”
The heart of Skai, and one of its most revolutionary features, is the use of hydrogen fuel cells, a clean environmental solution from end to end. With the advantage of being 95% reusable and the remaining (99%) recyclable, Skai’s hydrogen fuel cells offer reliable, safe and environmentally clean emission comprised solely of heat and water. This is a stark alternative to traditional fuel and battery sources. Hydrogen fuel cells allow Skai to travel further distances and carry a greater payload.
“Air mobility is a very exciting and fascinating topic,” said Holger Hampf, President of Designworks. “Our focus for this project was to help build a new consumer facing brand from scratch - considering and designing all touchpoints - digital, physical and service. And as a result, delivering an all-encompassing user-centric experience which is purposeful and highly desirable in all aspects.”
Alaka’i Technologies has initiated their test program with the FAA. Pending certification, Skai will create new possibilities in personal mobility for everyone, efficient emergency responses, economical freight distribution, and the utilization of hydrogen fuel cells as a highly reliable, zero-emission power source.
Skai Highlights Include:
- Co-designed by Designworks with inherent quality craftsmanship
- Powered by clean hydrogen fuel cells, with zero emissions
- Range: Up to 4 Hours, ~400 Miles
- Six reliable, quiet, efficient electric motors with designed-in redundancy
- Seats up to five passengers
- Reliable, fault-tolerant architecture for safety and security
- Piloted version launched first, with autonomous versions to follow
- Designed for the ultimate in safety, with an Airframe Parachute
For more information: http://skai.co .
ABOUT ALAKA’I
Alaka’i Technologies is an emerging air mobility design and manufacturing company, headquartered in Hopkinton MA. Founded by Brian Morrison in 2015, Alaka’i Technologies assembled a distinguished executive team with decades of aerospace development, production, executive and airspace integration experience (NASA, Raytheon, Beech Aircraft, McDonnell Douglas, Hughes, DayJet, SATSAir, Cirrus, Metro Aviation, Delta Airlines) and FAA certification experience. Working together since the 1990’s on industry-defining projects such as the NASA AGATE and SATS Programs, they also built and flew the world’s first-ever Fly-By-Light aircraft. Today, the Alaka'i team is engineering proprietary, progressive air mobility solutions to offer point A-to-Anywhere transportation that are clean, simple, safe, and accessible for everyone. Ultimately, transforming transportation through hydrogen-powered mobility.
ABOUT DESIGNWORKS
Designworks is the design innovation studio for the BMW Group. Designworks is ‘the architect of future’ — designing holistic systems that impact and improve the world we live in. Designworks inspires and challenges the companies it works with to be and stay at the forefront of their industries in design, technology and innovation. For 25 years it has been stimulating the BMW Group as well as a select group of companies with ambitious visions for the future.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005834/en/
Contact:
John Moore Press@alakai.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom